目的观察多塞平、美常安联合治疗腹泻型肠易激综合征(IBS-D)的疗效和不良反应。方法 156例IBS-D随机分为3组,多塞平联合美常安治疗组、单用多塞平组、单用美常安组各52例。口服药物剂量:多塞平25mg,1次/d;美常安500mg,3次/d。治疗4周后比较疗效。结果多塞平联合美常安治疗组总有效率94.2%,单用多塞平组总有效率73.1%,单用美常安组总有效率78.8%,多塞平联合美常安组总有效率与单用多塞平组及单用美常安组比较,差异有统计学意义(P<0.05),而单用多塞平组总有效率与单用美常安组相比,差异无统计学意义(P>0.05)。3组均未发现明显不良反应。结论多塞平、美常安联合治疗IBS-D有较好疗效,值得推广应用。 Objective To observe the curative effect and adverse reactions of docetaxel and moxalan in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Methods One hundred and sixty-six patients with IBS-D were randomly divided into three groups. Docetaxel combined with Chang-An-Mei treatment group and metoclopramide alone group and 52 cases with single-use Chang-An group. Oral drug dose: doxepin 25mg, 1 / d; beauty Changan 500mg, 3 times / d. After 4 weeks of treatment more effective. Results The total effective rate was 94.2%. The total effective rate of single-agent combination group was 73.1%. The total effective rate was 78.8%. The total effective rate of combination group was The difference was statistically significant (P <0.05) between the doxepin group and the single use of Changsan group, while the total effective rate of the single-dose doxepin group was no significant difference > 0.05). No obvious adverse reactions were found in 3 groups. Conclusions Docetaxel and the combination of moxibustion and IBS-D have a good curative effect and should be widely applied.